See the DrugPatentWatch profile for Cyramza
What patent does “Cyramza” refer to, and who holds it?
“Cyramza” is the brand name for ramucirumab, a monoclonal antibody. Patent ownership and the specific patents covering ramucirumab can vary by country and by claim type (for example, the molecule itself, specific medical uses, or manufacturing/process improvements). The information needed to identify the exact patent(s) you mean depends on the jurisdiction (US, EP, UK, etc.) and the patent number or listing you’re looking at.
How long does a Cyramza patent last (typical rules)?
Most drug patents last up to 20 years from the earliest effective filing date, but real-world patent “life” can be extended by regulatory exclusivities and, in some jurisdictions, by patent term adjustments/extensions tied to regulatory review time. The exact end date for ramucirumab’s legal protection is therefore not the same as the raw 20-year term and must be checked against the relevant patent register for the country of interest.
Can biosimilars enter before Cyramza’s patents expire?
Biosimilar approval and launch can be shaped by:
- Regulatory pathways (approval can happen while some patents are still in force, depending on the jurisdiction).
- Patent “stacking”: even after one patent expires, other patents covering different aspects (formulations, dosing regimens, indications, or manufacturing) can block launch.
- Litigation and settlements, which can delay entry.
Whether a biosimilar can launch “early” depends on what patents are still active and whether they’ve been invalidated/overcome or excluded by agreement.
Which indication is covered by patents for Cyramza?
Cyramza is used in multiple cancers (commonly including gastric/esophagogastric junction cancers and non-small cell lung cancer, among others). Patent coverage can be broader or narrower depending on how the patents were drafted—for example, patents may be limited to a specific indication, combination therapy, or patient selection. Determining which indication a particular patent covers requires reading the patent claims or the “Orange Book”-style listing equivalents in the target jurisdiction.
Are there lawsuits about Cyramza patents?
Patent disputes are common in biologics where multiple patents cover a product family and biosimilar developers challenge or negotiate around those claims. To answer accurately, you would need:
- the country (US vs EU vs UK, etc.),
- the specific competitor or biosimilar name, and
- the patent numbers involved.
What’s the fastest way to find the exact Cyramza patent expiry date you need?
Send any of the following and I can narrow it down precisely:
- the country/region (e.g., US, EP, UK),
- the patent number or a link to the patent listing you found,
- whether you’re looking for composition, method/use, or process patents,
- the indication (e.g., gastric cancer vs NSCLC) if relevant.
What if you mean “patent” as in “patent protected manufacturing method”?
If your goal is to understand whether a manufacturer can make and sell ramucirumab without infringement, patents may cover:
- the antibody sequence/structure (composition),
- production cell lines and processes,
- formulation/stability and delivery,
- specific dosing regimens or combination regimens.
Those can expire on different schedules, so the controlling patent may depend on how the biosimilar is made and how it’s marketed.
Next question to confirm
Which jurisdiction are you asking about (US, Europe/EP, UK, or another country), and do you have a specific patent number or link?